Zhifang Deng1, Cheng Yuan2, Jian Yang3, Yan Peng1, Wei Wang3, Yan Wang1, Wenqi Gao3. 1. Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang 443000, China. 2. Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China. 3. Department of Central Experimental Laboratory, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang 443000, China.
Abstract
BACKGROUND: The aim of this study was to evaluate the protective effects of Momordica charantia polysaccharides (MCP) on depressive-like behaviors. METHODS: The chronic social defeat stress (CSDS) mice model was used to evaluate the effects of MCP and their underlying mechanisms. Social interaction test (SIT), sucrose preference test (SPT), and tail suspension test (TST) were performed for behavioral assessments. Expression levels of inflammation mediators and phosphatidylinositol 3-kinase (PI3K) activity were determined using commercial ELISA kits. The expression of key proteins in the c-Jun N-terminal protein kinase (JNK3)/PI3K/protein kinase B (AKT) pathway were measured using western blot and RT-PCR. RESULTS: The results showed that chronic administration of MCP (100, 200, 400 mg/kg/day) significantly prevented depressive-like behaviors in CSDS mice as assessed by SIT, TST and SPT. Elevated levels of proinflammatory cytokines [tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β)], and expression of JNK3, c-Jun, P-110β proteins were observed in the hippocampus of CSDS mice. Moreover, the activity of PI3K and phosphorylation level of AKT were reduced in the hippocampus of CSDS mice. Interestingly, the administration of MCP reversed these changes. Furthermore, the protective effects of MCP on CSDS mice were partly inhibited by the PI3K inhibitor, LY294002. CONCLUSIONS: In conclusion, the protective effects of MCP against depressive-like behaviors in CSDS mice might be due to a reduction in neuroinflammation and the down-regulation of the JNK3/PI3K/AKT pathway in the hippocampus.
BACKGROUND: The aim of this study was to evaluate the protective effects of Momordica charantia polysaccharides (MCP) on depressive-like behaviors. METHODS: The chronic social defeat stress (CSDS) mice model was used to evaluate the effects of MCP and their underlying mechanisms. Social interaction test (SIT), sucrose preference test (SPT), and tail suspension test (TST) were performed for behavioral assessments. Expression levels of inflammation mediators and phosphatidylinositol 3-kinase (PI3K) activity were determined using commercial ELISA kits. The expression of key proteins in the c-Jun N-terminal protein kinase (JNK3)/PI3K/protein kinase B (AKT) pathway were measured using western blot and RT-PCR. RESULTS: The results showed that chronic administration of MCP (100, 200, 400 mg/kg/day) significantly prevented depressive-like behaviors in CSDS mice as assessed by SIT, TST and SPT. Elevated levels of proinflammatory cytokines [tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β)], and expression of JNK3, c-Jun, P-110β proteins were observed in the hippocampus of CSDS mice. Moreover, the activity of PI3K and phosphorylation level of AKT were reduced in the hippocampus of CSDS mice. Interestingly, the administration of MCP reversed these changes. Furthermore, the protective effects of MCP on CSDS mice were partly inhibited by the PI3K inhibitor, LY294002. CONCLUSIONS: In conclusion, the protective effects of MCP against depressive-like behaviors in CSDS mice might be due to a reduction in neuroinflammation and the down-regulation of the JNK3/PI3K/AKT pathway in the hippocampus.
Authors: B L Bennett; D T Sasaki; B W Murray; E C O'Leary; S T Sakata; W Xu; J C Leisten; A Motiwala; S Pierce; Y Satoh; S S Bhagwat; A M Manning; D W Anderson Journal: Proc Natl Acad Sci U S A Date: 2001-11-20 Impact factor: 11.205
Authors: Tiziana Borsello; Peter G H Clarke; Lorenz Hirt; Alessandro Vercelli; Mariaelena Repici; Daniel F Schorderet; Julien Bogousslavsky; Christophe Bonny Journal: Nat Med Date: 2003-08-24 Impact factor: 53.440
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Anne B Vojtek; Jennifer Taylor; Stacy L DeRuiter; Jenn-Yah Yu; Claudia Figueroa; Roland P S Kwok; David L Turner Journal: Mol Cell Biol Date: 2003-07 Impact factor: 4.272
Authors: Megan K Mulligan; Lu Lu; Sonia A Cavigelli; Pierre Mormède; Elena Terenina; Wenyuan Zhao; Robert W Williams; Byron C Jones Journal: Alcohol Clin Exp Res Date: 2019-05-21 Impact factor: 3.455
Authors: Renata L de Oliveira; Guilherme T Voss; Karline da C Rodrigues; Mikaela P Pinz; Julia V Biondi; Nicole P Becker; Eduardo Blodorn; William B Domingues; Allya Larroza; Vinícius F Campos; Diego Alves; Ethel A Wilhelm; Cristiane Luchese Journal: Psychopharmacology (Berl) Date: 2022-01-11 Impact factor: 4.530
Authors: Nicholas S Moore; Robert A Mans; Mackenzee K McCauley; Colton S Allgood; Keri A Barksdale Journal: Cells Date: 2021-03-12 Impact factor: 6.600